Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthopediatrics (KIDS) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $18.7 million.

  • Orthopediatrics' Cost of Revenue rose 1135.52% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 1790.52%. This contributed to the annual value of $64.3 million for FY2024, which is 2171.74% up from last year.
  • According to the latest figures from Q3 2025, Orthopediatrics' Cost of Revenue is $18.7 million, which was up 1135.52% from $19.1 million recorded in Q2 2025.
  • Over the past 5 years, Orthopediatrics' Cost of Revenue peaked at $19.1 million during Q2 2025, and registered a low of $8.9 million during Q1 2021.
  • Over the past 5 years, Orthopediatrics' median Cost of Revenue value was $12.8 million (recorded in 2023), while the average stood at $13.5 million.
  • Examining YoY changes over the last 5 years, Orthopediatrics' Cost of Revenue showed a top increase of 9352.31% in 2021 and a maximum decrease of 586.24% in 2021.
  • Over the past 5 years, Orthopediatrics' Cost of Revenue (Quarter) stood at $10.0 million in 2021, then rose by 20.03% to $12.0 million in 2022, then grew by 6.79% to $12.8 million in 2023, then soared by 31.13% to $16.8 million in 2024, then rose by 11.13% to $18.7 million in 2025.
  • Its Cost of Revenue stands at $18.7 million for Q3 2025, versus $19.1 million for Q2 2025 and $16.6 million for Q1 2025.